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Abstract
Background: The immunosuppressive and anti-inflammatory properties of mesenchymal stromal cells (MSC) have
prompted their therapeutic application in several autoimmune diseases, including rheumatoid arthritis. Adult MSC
are finite and their clinical use is restricted by the need for long-term expansion protocols that can lead to genomic
instability. Inhibition of Smad2/3 signaling in human pluripotent stem cells (hPSC) provides an infinite source of
MSC that match the phenotype and functional properties of adult MSC. Here, we test the therapeutic potential of
hPSC-MSC of embryonic origin (embryonic stem cell-derived mesenchymal stromal cells, hESC-MSC) in the
experimental model of collagen-induced arthritis (CIA).
Methods: CIA was induced in DBA/1 mice by immunization with type II collagen (CII) in Complete Freund’s
Adjuvant (CFA). Mice were treated with either a single dose (106 cells/mouse) of hESC-MSC on the day of
immunization (prophylaxis) or with three doses of hESC-MSC every other day starting on the day of arthritis onset
(therapy). Arthritis severity was evaluated daily for six weeks and ten days, respectively. Frequency of Treg (FoxP3+),
Th1 (IFNγ+) and Th17 (IL17+) CD4+ T cells in inguinal lymph nodes (ILN) was quantified by flow cytometry. Serum
levels of anti-CII antibodies were determined by ELISA. Detection of hESC-MSC and quantification of murine and
human indoleamine 2,3 dioxygenase (IDO1) expression was performed by quantitative real-time PCR. Statistical
differences were analyzed by ANOVA and the Mann-Whitney U test.
Results: Administration of hESC-MSC to mice with established arthritis reduced disease severity compared to
control-treated mice. Analysis of CD4 T cell populations in treated mice showed an increase in FoxP3+ Treg and
IFNγ+ Th1 cells but not in Th17 cells in the ILN. Anti-CII antibody levels were not affected by treatment. Migration
of hESC-MSC to the ILN in treated mice was associated with the induction of murine IDO1.
Conclusion: Treatment with hESC-MSC ameliorates CIA by inducing IFNγ+ Th1 cells and IDO1 in the host. Thus,
hESC-MSC can provide an infinite cellular source for treatment of rheumatoid arthritis.
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Background
Mesenchymal stromal cells (MSC) are multipotent pro-
genitor cells that can differentiate into lineages of mes-
enchymal tissues, including bone, cartilage, and adipose
tissues [1]. MSC have been isolated from a variety of
adult tissues, such as bone marrow, skeletal muscle,
synovium, dental pulp, liver, muscle, brain, placenta,
bone, umbilical cord, and adipose tissue [2, 3]. MSC lack
immunogenicity, display robust immunosuppressive and
anti-inflammatory properties, promote angiogenesis, and
reduce apoptosis, a set of features that have prompted
their wide use in regenerative medicine [4–6]. MSC play
a regulatory role on immune responses by producing
soluble factors, including transforming growth factor
(TGF)-β, hepatocyte growth factor, nitric oxide, hemoxy-
genase, IL6, prostaglandin E2, and HLA-G [7–9]. In
addition, MSC can produce high levels of indoleamine
2,3 dioxygenase (IDO1), a tryptophan catabolizing en-
zyme that mediates immune tolerance by limiting the
availability of the essential amino acid tryptophan and
generating toxic metabolites for T cells [10].
Due to their immunosuppressive properties and low
immunogenicity, MSC have been proposed as thera-
peutic agents for autoimmune diseases such as multiple
sclerosis, autoimmune diabetes, systemic lupus erythe-
matosus, and rheumatoid arthritis (RA) [11–13]. Re-
cently, several studies have investigated the therapeutic
role of MSC in the treatment of collagen induced-
arthritis (CIA), a well-characterized model of chronic
arthritis [14, 15]. One recent study has demonstrated
that adult bone marrow allogeneic MSC migrate to the
affected paws and reduce the severity of arthritis in CIA
[16]. It has also been shown that human umbilical cord-
derived and adipose-tissue-derived MSC reduce the inci-
dence and severity of arthritis in mice by inhibiting pro-
inflammatory cytokines and inducing activation of
regulatory T cells (Treg) [17–19]. Adult MSC are finite
and their potential clinical use requires long-term ex-
pansion protocols, which might be associated with in
vitro acquired genomic instability and reactivation of im-
munogenicity [20]. Recently, through inhibition of
Smad-2/3 signaling, MSC were reproducibly derived
from human pluripotent stem cells (hPSC) spanning
both embryonic stem cells (hESC) and induced pluripo-
tent stem cells (iPSC) [6, 21]. Human PSC represent an
infinite source for MSC, and hPSC-MSC display an
identical phenotype, functional properties, and in vitro
and in vivo immunosuppressive and anti-inflammatory
features compared to adult bone-marrow-derived or
cord-blood-derived MSC, as demonstrated in experi-
mental models of acute inflammation in vivo when ad-
ministered prophylactically [6]. These findings prompted
us to investigate the potential therapeutic use of hESC-
MSC in the setting of the chronic inflammatory model
of CIA. Administration of hESC-MSC in mice with
established disease reduced the severity of arthritis and
increased the frequency of Treg and T helper (Th)1 cells
without affecting Th17 cells. hESC-MSC administered to




hESC-MSC were differentiated in vitro and phenotypic-
ally/functionally characterized as previously described
[6]. hESC-MSC were cultured in Advanced-DMEM with
10 % FCS, 1 % Glutamax, and 1 % penicillin/strepto-
mycin and were allowed to expand and reach nearly
100 % confluence. hESC-MSC at passage ≤10 were used
for the in vivo experiments.
Mice
DBA/1OlaHsd mice were purchased from Harlan la-
boratories and maintained under specific pathogen-free
conditions in the Animal Facility of the Hospital 12 de
Octubre. All animal experiments followed institutional
guidelines and were approved by the Hospital 12 de
Octubre Animal Welfare Committee.
CIA induction and treatment
Ten-week-old male mice were immunized by intrader-
mal injection at the base of the tail with 200 μg of
chicken CII in Complete Freund’s Adjuvant (CFA), as
previously described [22]. Mice were treated with 106
hESC-MSC or PBS (control mice) intraperitoneally (i.p.)
on the day of immunization and euthanized 6 weeks
later (prophylactic protocol) or treated on days 1, 3 and
5 starting on the day of arthritis onset and killed 10 days
later (therapeutic protocol). Joint inflammation was
measured daily starting on the day of arthritis onset,
using a 0–10-mm microcalliper (Mitutoyo, Japan). The
clinical severity of arthritis was graded daily for each
paw by two independent observers using the following
scoring system: 0 = normal, 1 = slight swelling and ery-
thema, 2 = pronounced edematous swelling, and 3 = stiff-
ness of the joint, yielding a maximum score of 12 per
mouse. Disease severity was expressed as the mean clin-
ical score ± the standard error of the mean (SEM) per
group of treatment [22]. Seven to ten mice per group
were included in each experiment.
Histological joint inflammation and cartilage damage
Paws were removed and fixed overnight in 4 % formal-
dehyde, decalcified with Immunocal (Decal Chemical
Corp, NY, USA) and embedded in paraffin. Sections
(5 μm) were prepared and stained with hematoxylin-
eosin for assessment of inflammation and histological
damage.
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CII-specific responses
Serum was collected from mice with CIA after 10 days
of treatment and levels of anti-collagen IgG1 and IgG2a
antibodies were assessed by ELISA as previously de-
scribed [22]. A standard curve was generated for each
assay by including serial dilutions of a reference sample
of pooled sera from arthritic mice. Relative antibody
units (AU) were obtained for each sample by reference
to the standard curve.
To address CII-specific responses in draining inguinal
lymph nodes (ILN), single cell suspensions were cultured
in the presence of 50 μg/ml CII. The specific prolifera-
tive response to CII was determined by the incorpor-
ation of WST-1 (Roche, Mannheim, Germany) after
72 hours. Cytokine production in culture supernatants
collected after 48 hours was measured by ELISA (inter-
feron (IFN)γ and IL17, ELISAMax Standard Kits, Biole-
gend, CA, USA.) and flow cytometry (IL2, mouse Th1/
Th2/Th17 13plex kit, Affimetrix, CA, USA).
Flow cytometry
Single cell suspensions from ILN were stimulated with
20 ng/ml PMA (Sigma-Aldrich) and 1 μg/ml ionomycin
(Sigma-Aldrich) in the presence of 10 μg/ml brefeldin A
(Sigma-Aldrich) for 4 hours at 37 °C, 5 % CO2. Cells were
stained with anti-CD4-PerCP antibody (clone RM4-5, BD
Biosciences, San Diego, CA, USA), permeabilized with
0.5 % saponin and stained with anti-IFNγ-fluorescein
isothiocyanate (FITC) (clone XMG1.2, BD Biosciences)
and anti-IL17-PE (clone TC11-18H10, MiltenyiBiotec,
Bergisch Gladbach, Germany) antibodies.
To detect Treg, single cell suspensions from ILN were
stained with anti-CD4-PerCP and anti-CD25-FITC
(clone 7D4, BD Biosciences) antibodies, fixed, perme-
abilized and stained with anti-Foxp3-PE antibody
(cloneMF-23, BD Biosciences) following the manufac-
turer’s instructions. Isotype controls were included in
all experiments to adjust the background signal. Flow
cytometer analysis was performed in a FACSCalibur
instrument and analyzed with Cell Quest Pro software
(BD Biosciences).
Quantitative real-time polymerase chain reaction (RT-qPCR)
ILN and paws were snap frozen in liquid nitrogen,
pulverized, and total RNA extracted using TRI re-
agent (Sigma-Aldrich, Madrid, Spain): 1 μg was used
for first-strand complementary DNA (cDNA) synthe-
sis with the High Capacity cDNA Transcription Kit
(Applied Biosystems; Warrington, UK) and quantita-
tive RT-qPCR was performed on an Applied Biosys-
tems 7500 Fast Real-Time PCR System using Power
SYBR Green PCR Master Mix. Data obtained were
normalized to a standard curve obtained by serial
dilution of a template cDNA and expressed as the
ratio between the target gene and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Primer sequences
were as follows: Human IDO1(hIDO1): forward: 5′-
GCCCTTCAAGTGTTTCAC-3′, reverse: 5′-CCAGCCA
GACAAATATATGCGA-3′; mouse IDO (mIDO1): for-
ward: 5′-CAAAGCAATCCCCACTGTATCC-3′, reverse:
5′-ACAAAGTCACGCATCCTCTTAAA-3′; human GAP
DH (hGAPDH): forward: 5′-TGTTGCCATCAATGAC
CCCTT-3′, reverse: 5′-CTCCACGACGTACTCAGCG-3′;
mouse GAPDH: (mGAPDH) forward: 5′-CATGGCCTT
CCGTGTTCCTA-3′, reverse: 5′-GCGGCACGTCAGATC
CA-3′; HLA-C: forward: 5′-GCAGCACGAGGGGCTGC
AAG-3′; reverse: 5′-TTGCTGCACGCAGCCTGAGA-3′.
Statistical analysis
Descriptive analysis of each experiment was performed
to compare the incidence and severity of the disease.
The impact of hESC-MSC on the clinical scores for mice
with CIA and the course of disease was analyzed by
two-way analysis of variance (ANOVA) for repeated
measures. Differences between groups were compared
using the Mann-Whitney U test for two independent
samples or one-way ANOVA using the Kruskal-Wallis
non-parametric test, as required. Analysis was performed
using GraphPad Prism software (version 6.0, Graph
Pad; CA, USA). P values below 0.05 were considered
statistically significant.
Results
hESC-MSC ameliorate established collagen-induced arthritis
To test the ability of hESC-MSC to modulate the pro-
gression of arthritis after CII immunization, DBA/1 mice
were treated prophylactically with 106 cells at the time
of immunization, and the evolution of arthritis was
assessed daily for 6 weeks. Arthritis incidence was com-
parable between groups, reaching 90 % by the end of the
experiment (Fig. 1a). Likewise, the severity of arthritis
was comparable between experimental groups, and no
protective effect was observed after prophylactic admin-
istration of hESC-MSC (Fig. 1a). These data suggest that
inflammatory signals may underlie the hESC-MSC-
mediated immunosuppressive response, as widely sug-
gested [23]. To test this hypothesis, we administered
hESC-MSC to DBA/1 mice starting on the day of arth-
ritis onset (clinical score ≥1) and examined the clinical
response of mice with established CIA. Treatment with
a single dose of hESC-MSC (106 cells) significantly re-
duced arthritis severity and slowed the disease progres-
sion in comparison to the control group (Fig. 1b).
Disease improvement was noticed the first day after
hESC-MSC infusion and was maintained up to day 6
after arthritis onset. Administration of three doses of
hESC-MSC (106 cells every other day) resulted in a more
pronounced and significant clinical amelioration that
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was sustained for the duration of the experiment
(Fig. 1b and c). In agreement with these observations,
on histological analysis of the joints there was re-
duced cellular infiltration and decreased bone and
cartilage destruction in hESC-MSC-treated mice com-
pared to the control group (Fig. 1d). Together, these
data suggest a robust therapeutic anti-inflammatory
effect of hESC-MSC in controlling the progression of
established arthritis.
hESC-MSC induce accumulation of Treg and Th1 cells in
draining lymph nodes
To characterize the mechanism underlying the protect-
ive role of hESC-MSC in CIA, we evaluated the fre-
quency of regulatory and effector CD4+ T cells in
draining the ILN of mice with CIA. Increased frequen-
cies of both Treg cells (CD4+ Foxp3+) and Th1 cells
(CD4+ IFNγ+) were found in the hESC-MSC-treated
group compared to the PBS-treated group (Treg 9.66 ±
Fig. 1 Administration of embryonic stem cell-derived mesenchymal stromal cells (hESC-MSC) ameliorates established collagen-induced arthritis
(CIA). a Progression of arthritis after prophylactic administration of hESC-MSC in one experiment representative of two performed. Incidence
(left panel) and arthritis score (right panel) were comparable to the control group when hESC-MSC were administered on the day of type II collagen
(CII) immunization. b Dose-response effect of the therapeutic administration of hESC-MSC on arthritis score. Statistical differences between control and
single-dose groups are indicated. c Amelioration of CIA induced by administration of three doses (arrowheads) of hESC-MSC is sustained in mice with
established disease. Data pooled from three independent experiments with four to ten mice per experimental group. d Representative hematoxylin-eosin
staining of joints after treatment with hESC-MSC in mice with established disease. *P < 0.05; **P < 0.01; ***P < 0.001
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0.65 % vs 7.72 ± 0.58 %, P = 0.009; Th1 0.71 ± 0.07 % vs
0.46 ± 0.03 %, P = 0.007). However, no significant differ-
ences in Th17 cells (CD4+ IL17+) were detected (0.75 ±
0.07 % vs 0.79 ± 0.05 %, P = 0.45) (Fig. 2a). Importantly,
an increased Treg/Th17 ratio was observed in the hESC-
MSC with respect to the control group (13.59 ± 1.90 vs
8.58 ± 0.74, P = 0.04), an indicator that has been previ-
ously linked to therapeutic efficacy in human RA [24].
In contrast, no difference in Treg/Th1 ratio was found
between the experimental groups (Fig. 2b).
To gain insights into the antigen specificity of the
alterations observed in the homeostasis of T cell subsets,
T cell proliferation and cytokine production was evalu-
ated in the ILN upon in vitro stimulation with CII.
Although there was a specific proliferative response to
CII compared to non-stimulated cells (NS) (Fig. 3a), no
significant differences were observed between experi-
mental groups (hESC-MSC 0.12 ± 0.03; PBS 0.14 ± 0.04,
P = 0.97). Accordingly, similar levels of IL2 were detected
after CII stimulation (hESC-MSC 44.96 ± 17.92 pg/ml;
PBS 39.13 ± 17.29 pg/ml, P = 0.50). Furthermore, no
significant differences were observed in response to
CII in the production of IL17 (138.20 ± 78.14 pg/ml
in hESC-MSC-treated vs 43.37 ± 40.61 pg/ml in PBS-
treated mice, P = 0.26) and IFNγ (261.60 ± 121.60 pg/
ml in the hESC-MSC group vs 94.17 ± 53.79 pg/ml in
the PBS group, P = 0. 67) (Fig. 3a).
Analysis of the humoral response in the sera from
mice with CIA showed comparable titers of anti-CII
IgG1 (13.85 ± 1.92 AU in hESC-MSC vs 14.79 ±
1.88 AU in PBS, P = 0.68) and IgG2a (14.29 ± 1.89 AU
in hESC-MSC vs 18.05 ± 2.52 AU in PBS, P = 0.35)
(Fig. 3b). Together, these data indicate that administra-
tion of hESC-MSC in arthritic mice promotes preferen-
tial accumulation of Treg and Th1 cells in the ILN and
increases the Treg/Th17 ratio without altering the pro-
file of anti-CII antibodies.
hESC-MSC migrate to ILN and induce expression of
indoleamine 2,3 dioxygenase
The observation that Treg and Th1 cell frequencies are
increased in the ILN of hESC-MSC-treated mice without
affecting CII-specific responses suggests that hESC-MSC
migrate to the draining ILN at the site of inflammation
and promote an antigen-independent immunoregulatory
state. As IFNγ induces IDO1-mediated immunoregula-
tion in bone marrow (BM)-MSC [10], we hypothesized
that the accumulation of IFNγ+ Th1 cells in the ILN
may induce the expression of IDO1 by hESC-MSC. To
further explore this hypothesis, expression of human-
specific HLA-C transcripts was analyzed by RT-qPCR to
ascertain the presence of hESC-MSC in the paws and
ILN of treated mice. Although HLA-C transcripts were
not detected in the paws in any experimental condition
Fig. 2 Embryonic stem cell-derived mesenchymal stromal cells (hESC-MSC) administration alters the regulatory T cell (Treg)/effector T cell (Teff)
balance in mice with collagen-induced arthritis. The frequency of Treg and Teff cells was analyzed by flow cytometry in the inguinal lymph nodes
(ILN) 10 days after arthritis onset in mice with established disease. a Representative flow cytometry plots and quantification of CD4 Treg
and Teff cell frequency in hESC-MSC-treated and control mice. b Treg/T helper (Th)17 ratio is significantly increased in hESC-MSC-treated
mice compared to the control group. Data shown are values from individual mice and the mean of experimental groups. Statistical differ-
ences were analyzed by the Mann-Whitney U test. *P < 0.05; **P < 0.01. PBS phosphate-buffered saline, IFN interferon
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(data not shown), they were specifically present in the
ILN of most mice treated with hESC-MSC (Fig. 4a),
strongly suggesting selective migration of hESC-MSC to
the ILN. However, IDO1 expression of human origin
(hIDO) was not detected either in the ILN of mice with
expression of HLA-C trancripts or in any other
experimental condition (data not shown). Surprisingly,
detection of HLA-C in the ILN (HLA+) was associated
with increased expression of mouse IDO compared to
control-treated mice (P < 0.05) and hESC-MSC-treated
non-colonized mice (HLA–) (P < 0.01) (Fig. 4b), indicat-
ing that IFNγ+ Th1 cells induced by hESC-MSC pro-
mote expression of mouse IDO1 by endogenous cells.
Discussion
MSC possess broad immunoregulatory abilities and can
influence both adaptive and innate immune responses.
Previous studies have extensively investigated the use of
adult MSC as cellular therapy in several inflammatory
diseases, including RA [25, 26]. As MSC may migrate to
sites of injury in vivo, it is reasonable to suggest that
targeting the cells to inflamed joints might have a
therapeutic effect on arthritis through MSC-mediated
immunosuppression. Several groups have recently
demonstrated the in vivo therapeutic effect of human
cord-blood- and bone-marrow-derived MSC in arth-
ritis [14, 17, 27]. In contrast, some other groups have
pointed out an adverse effect when MSC are adminis-
tered in mice with CIA [28, 29]. These conflicting
data reinforce the need for further research into the
role of MSC in chronic arthritis.
MSC derived from hPSC represent an infinite cellular
source and have been successfully derived by our group
Fig. 3 Type II collagen (CII)-specific T cell responses in vitro and anti-CII antibody levels in embryonic stem cell-derived mesenchymal stromal
cells (hESC-MSC)-treated mice. a Proliferation and cytokine production in response to CII by inguinal lymph node cells from hESC-MSC and
phosphate-buffered saline (PBS)-treated mice with established collagen-induced arthritis. Data represent the mean ± the standard error of the
mean of the experimental groups. b Comparable levels of anti-CII IgG1 and IgG2a were measured in sera from control and hESC-MSC-treated
mice. Data shown are values from individual mice and the mean of experimental groups. Statistical differences were analyzed by the Mann-Whitney U
test and no significant differences were found. NS non-stimulated
Fig. 4 Embryonic stem cell-derived mesenchymal stromal cells
(hESC-MSC) migrate to the inguinal lymph nodes (ILN) and induce
expression of murine indoleamine 2,3 dioxygenase (IDO1). a Expression
of HLA-C transcripts in the ILN of mice with collagen-induced arthritis
(CIA) treated with hESC-MSC compared to the phosphate-buffered
saline (PBS)-treated group. b Expression of murine IDO1 (mIDO1) in the
ILN of mice with CIA treated with vehicle (PBS) or with hESC-MSC and
showing evidence of migration (HLA+) or not (HLA–). Data show values
from individual mice and the mean of the experimental groups.
Statistical differences were analyzed by Kruskall-Wallis analysis of
variance and Dunn’s multiple comparisons test. *P < 0.05; **P < 0.01
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upon specific inhibition of SMAD2/3 signaling [6, 21].
hESC-MSC display the same phenotype and differenti-
ation potential as adult MSC [6, 20, 30]. Importantly,
they show immunosuppressive and anti-inflammatory
properties in vitro and have demonstrated a protective
role in vivo in an acute model of inflammation [6].
To elucidate the effect of hESC-MSC in a chronic
model of arthritis, mice with CIA were treated with
hESC-MSC at different stages of arthritis development.
Our results demonstrated amelioration of established
arthritis after hESC-MSC infusion compared to control-
treated mice (therapeutic effect). However, prophylactic
administration of these cells during the induction phase
of CIA did not affect disease incidence or severity. Ac-
cording to previous findings, the contrasting results of
prophylactic vs therapeutic treatment suggest that
hESC-MSC might induce differential effects depending
on the time of administration and their state of activa-
tion [31–33]. In this sense, it has been demonstrated that
MSC become activated in an inflammatory environment,
and suppress T cell proliferation. In this scenario, MSC
adopt an immune-suppressive phenotype by secreting
high levels of soluble factors [23]. This could explain the
anti-inflammatory effect of hESC-MSC in established
arthritis and the absence of such an effect when adminis-
tered prophylactically (during the induction of the disease)
within a non-inflammatory environment.
Treatment with hESC-MSC altered the T cell subsets
in the ILN of mice with established arthritis. Notably,
there was increased frequency of Treg, in agreement
with previous reports demonstrating that human
adipose-derived MSC cells reduce the severity of CIA
and generate Treg cells de novo [15]. Likewise, infusion
of gingiva derived-MSC has also resulted in increased
levels of CD4+ CD39+ FoxP3+ cells in the spleen, ILN
and synovial fluid of arthritic mice [34]. Our finding that
Th1 IFNγ+ cells are also increased in the ILN of hESC-
MSC-treated mice is consistent with the protective role
of IFNγ in CIA [35–37] and some reports of therapeutic
use of recombinant IFNγ in human RA [38, 39]. Fur-
thermore, elevated production of IFNγ by Th1 cells can
also contribute to the elevated frequencies of Treg cells
in hESC-MSC-treated mice [40].
It has been recently reported that IDO1 induction is
involved in the regulation of IL17 by IFNγ [36]. In our
study, mice treated with hESC-MSC had similar levels of
IL17 regardless of the higher expression of IFNγ. The
reason for such a discrepancy may lie in the experimental
conditions used by Lee et al. to address the role of IDO1.
We evaluated differentiated Th17 cells and their IL17
production in secondary lymph nodes (LN), whereas Lee
et al. measured IL17 production by CD4 T cells isolated
from naive mice under in vitro Th17 polarizing conditions
[36]. In addition, elevated levels of IL17 production by
DBA/1 mice may prove more resistant to inhibition than
in the C57Bl6 mice used by Lee et al. [37].
We investigated whether hESC-MSC were able to mi-
grate to draining lymph nodes to promote an antigen-
independent immunoregulatory state. Results confirmed
HLA expression in hESC-MSC-treated CIA mice, indi-
cating migration of hESC-MSC to ILN at the end of the
experiments, 5 days after the last infusion. Although we
have not determined the presence of human cells in
mice beyond this time point, recent evidence indicates that
human MSC are not detected in the organs of mice with
CIA by 10 days after administration [41], an observation
that can explain the increased efficiency of repeated doses
of hESC-MSC to achieve sustained amelioration of arthritis
and the lack of efficacy of the prophylactic treatment.
As IFNγ and CTLA-4 expression on Treg are the main
promoters of IDO1 expression, the induction of IFNγ+
Th1 and Treg cells by hESC-MSC infusion suggests that
the immunoregulatory function of hESC-MSC might be
mediated by IDO1 [42, 43]. Evidence of IDO1-
dependent amelioration of CIA has been recently shown
by treatment with TGF-β-induced Treg [44]. Moreover,
we have previously demonstrated that IDO1 expression
is induced during CIA in dendritic cells (DC) in the ILN
and that genetic knockdown or pharmacological inhib-
ition of IDO activity is associated with increased severity
of CIA [45]. Conversely, administration of the IDO1
product kynurenine or synthetic analogs of tryptophan
catabolites ameliorates arthritis [45, 46]. Mice with mi-
gration of hESC-MSC to the ILN had significantly
higher expression of IDO1 than hESC-MSC-treated
non-colonized mice or control-treated mice, indicating
an IDO1-mediated immunoregulatory function of hESC-
MSC in mice with CIA. Surprisingly, the source of IDO1
expression was of mouse origin and not the hESC-MSC
themselves, suggesting that hESC-MSC ameliorate CIA
by directly acting on the host T cells that in turn induce
expression of IDO by mouse DC. This finding raises the
possibility that the amelioration induced by hESC-MSC
in CIA could be the result of a non-specific response to
the injection of xenogeneic cells, independently of their
MSC phenotype. In accordance with most reports on
the therapeutic application of human MSC in CIA [19,
47, 48], our experimental setup did not include a treat-
ment group composed of other human cell types. How-
ever, Zhou et al. have shown that administration of
human cells of non-mesenchymal lineage is ineffective
in the treatment of established CIA [18]. Moreover, hu-
man umbilical-cord-MSC are required to be alive to
exert their therapeutic action in CIA [17]. Together,
these observations make it unlikely that their xenogeneic
origin plays a role in the protection triggered by hESC-
MSC, and point to the induction of a specific immuno-
regulatory response.
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In summary, our data show that hESC-MSC administra-
tion induces accumulation of Treg and Th1 cells and pro-
motes expression of endogenous IDO1 in draining lymph
nodes, thus, reducing disease progression and the severity
of CIA. Therefore, hESC-MSC can provide an infinite
cellular source for therapeutic interventions in RA.
Conclusions
Administration of hESC-MSC to mice with established
arthritis reduces disease severity. Injection of these cells
into arthritic mice promotes accumulation of Treg and
Th1 cells in the ILN, and modulates inflammation by
inducing the expression of indoleamine 2,3 dioxygenase in
the host.
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